US 12,600,801 B2Granted

Single-domain antibodies that bind ROR1

AssigneeFred Hutchinson Cancer Center

InventorsJason Price, Colin E. Correnti, James M. Olson

Life of this patent

Estimating the term…

Abstract

Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.

Claims20

Dependent claims

A single-domain antibody that binds receptor tyrosine kinase (ROR1), the single domain antibody comprising a set of complementarity determining regions (CDRs) comprising:

(i) a CDR1 having the sequence as set forth in SEQ ID NO:
6, a CDR2 having the sequence as set forth in SEQ ID NO:
7, and a CDR3 having the sequence as set forth in SEQ ID NO:
8 according to IMGT;
(ii) a CDR1 having the sequence as set forth in SEQ ID NO:
9, a CDR2 having the sequence as set forth in SEQ ID NO:
10, and a CDR3 having the sequence as set forth in SEQ ID NO:
11 according to Kabat;
(iii) a CDR1 having the sequence as set forth in SEQ ID NO:
12, a CDR2 having the sequence as set forth in SEQ ID NO:
13, and a CDR3 having the sequence as set forth in SEQ ID NO:
11 according to Chothia;
(iv) a CDR1 having the sequence as set forth in SEQ ID NO:
14, a CDR2 having the sequence as set forth in SEQ ID NO:
15, and a CDR3 having the sequence as set forth in SEQ ID NO:
8 according to North;
(v) a CDR1 having the sequence as set forth in SEQ ID NO:
16, a CDR2 having the sequence as set forth in SEQ ID NO:
17, and a CDR3 having the sequence as set forth in SEQ ID NO:
18 according to Contact;
(vi) a CDR1 having the sequence as set forth in SEQ ID NO:
19, a CDR2 having the sequence as set forth in SEQ ID NO:
20, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to IMGT;
(vii) a CDR1 having the sequence as set forth in SEQ ID NO:
22, a CDR2 having the sequence as set forth in SEQ ID NO:
23, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Kabat;
(viii) a CDR1 having the sequence as set forth in SEQ ID NO:
25, a CDR2 having the sequence as set forth in SEQ ID NO:
26, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Chothia;
(ix) a CDR1 having the sequence as set forth in SEQ ID NO:
27, a CDR2 having the sequence as set forth in SEQ ID NO:
28, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to North;
(x) a CDR1 having the sequence as set forth in SEQ ID NO:
29, a CDR2 having the sequence as set forth in SEQ ID NO:
30, and a CDR3 having the sequence as set forth in SEQ ID NO:
31 according to Contact;
(xi) a CDR1 having the sequence as set forth in SEQ ID NO:
32, a CDR2 having the sequence as set forth in SEQ ID NO:
20, and a CDR3 having the sequence as set forth in SEQ ID NO:
33 according to IMGT;
(xii) a CDR1 having the sequence as set forth in SEQ ID NO:
34, a CDR2 having the sequence as set forth in SEQ ID NO:
23, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Kabat;
(xiii) a CDR1 having the sequence as set forth in SEQ ID NO:
35, a CDR2 having the sequence as set forth in SEQ ID NO:
26, and a CDR3 having the sequence as set forth in SEQ ID NO:
33 according to Chothia;
(xiv) a CDR1 having the sequence as set forth in SEQ ID NO:
36, a CDR2 having the sequence as set forth in SEQ ID NO:
28, and a CDR3 having the sequence as set forth in SEQ ID NO:
33 according to North;
(XV) a CDR1 having the sequence as set forth in SEQ ID NO:
29, a CDR2 having the sequence as set forth in SEQ ID NO:
30, and a CDR3 having the sequence as set forth in SEQ ID NO:
37 according to Contact;
(xvi) a CDR1 having the sequence as set forth in SEQ ID NO:
32, a CDR2 having the sequence as set forth in SEQ ID NO:
20, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to IMGT;
(xvii) a CDR1 having the sequence as set forth in SEQ ID NO:
35, a CDR2 having the sequence as set forth in SEQ ID NO:
26, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Chothia;
or
(xviii) a CDR1 having the sequence as set forth in SEQ ID NO:
36, a CDR2 having the sequence as set forth in SEQ ID NO:
28, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to North
wherein the single-domain antibody is not linked to an IgM Fc region or multimerizing fragment thereof.

71 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/350,617Filed 11 Jul 2023 · us provisional application
Priority: 11 Jul 2022
Published: US 2024/0092941 A121 Mar 2024
Granted: 14 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
C07K 16/468
Hybrid immunoglobulins: immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily

Family

Application63/388,157Us provisional application · filed 11 Jul 2022
US 2024/0092941 A1Pre-grant publication · published 21 Mar 2024
US 12,600,801 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

A single-domain antibody that binds receptor tyrosine kinase (ROR1), the single domain antibody comprising a set of complementarity determining regions (CDRs) comprising:

(i) a CDR1 having the sequence as set forth in SEQ ID NO:
6, a CDR2 having the sequence as set forth in SEQ ID NO:
7, and a CDR3 having the sequence as set forth in SEQ ID NO:
8 according to IMGT;
(ii) a CDR1 having the sequence as set forth in SEQ ID NO:
9, a CDR2 having the sequence as set forth in SEQ ID NO:
10, and a CDR3 having the sequence as set forth in SEQ ID NO:
11 according to Kabat;
(iii) a CDR1 having the sequence as set forth in SEQ ID NO:
12, a CDR2 having the sequence as set forth in SEQ ID NO:
13, and a CDR3 having the sequence as set forth in SEQ ID NO:
11 according to Chothia;
(iv) a CDR1 having the sequence as set forth in SEQ ID NO:
14, a CDR2 having the sequence as set forth in SEQ ID NO:
15, and a CDR3 having the sequence as set forth in SEQ ID NO:
8 according to North;
(v) a CDR1 having the sequence as set forth in SEQ ID NO:
16, a CDR2 having the sequence as set forth in SEQ ID NO:
17, and a CDR3 having the sequence as set forth in SEQ ID NO:
18 according to Contact;
(vi) a CDR1 having the sequence as set forth in SEQ ID NO:
19, a CDR2 having the sequence as set forth in SEQ ID NO:
20, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to IMGT;
(vii) a CDR1 having the sequence as set forth in SEQ ID NO:
22, a CDR2 having the sequence as set forth in SEQ ID NO:
23, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Kabat;
(viii) a CDR1 having the sequence as set forth in SEQ ID NO:
25, a CDR2 having the sequence as set forth in SEQ ID NO:
26, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Chothia;
(ix) a CDR1 having the sequence as set forth in SEQ ID NO:
27, a CDR2 having the sequence as set forth in SEQ ID NO:
28, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to North;
(x) a CDR1 having the sequence as set forth in SEQ ID NO:
29, a CDR2 having the sequence as set forth in SEQ ID NO:
30, and a CDR3 having the sequence as set forth in SEQ ID NO:
31 according to Contact;
(xi) a CDR1 having the sequence as set forth in SEQ ID NO:
32, a CDR2 having the sequence as set forth in SEQ ID NO:
20, and a CDR3 having the sequence as set forth in SEQ ID NO:
33 according to IMGT;
(xii) a CDR1 having the sequence as set forth in SEQ ID NO:
34, a CDR2 having the sequence as set forth in SEQ ID NO:
23, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Kabat;
(xiii) a CDR1 having the sequence as set forth in SEQ ID NO:
35, a CDR2 having the sequence as set forth in SEQ ID NO:
26, and a CDR3 having the sequence as set forth in SEQ ID NO:
33 according to Chothia;
(xiv) a CDR1 having the sequence as set forth in SEQ ID NO:
36, a CDR2 having the sequence as set forth in SEQ ID NO:
28, and a CDR3 having the sequence as set forth in SEQ ID NO:
33 according to North;
(XV) a CDR1 having the sequence as set forth in SEQ ID NO:
29, a CDR2 having the sequence as set forth in SEQ ID NO:
30, and a CDR3 having the sequence as set forth in SEQ ID NO:
37 according to Contact;
(xvi) a CDR1 having the sequence as set forth in SEQ ID NO:
32, a CDR2 having the sequence as set forth in SEQ ID NO:
20, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to IMGT;
(xvii) a CDR1 having the sequence as set forth in SEQ ID NO:
35, a CDR2 having the sequence as set forth in SEQ ID NO:
26, and a CDR3 having the sequence as set forth in SEQ ID NO:
24 according to Chothia;
or
(xviii) a CDR1 having the sequence as set forth in SEQ ID NO:
36, a CDR2 having the sequence as set forth in SEQ ID NO:
28, and a CDR3 having the sequence as set forth in SEQ ID NO:
21 according to North
wherein the single-domain antibody is not linked to an IgM Fc region or multimerizing fragment thereof.

71 more elements

Facts

Application

18/350,617Filed 11 Jul 2023 · us provisional application

Priority

11 Jul 2022

Published

US 2024/0092941 A121 Mar 2024

Granted

14 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
C07K 16/468
Hybrid immunoglobulins: immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily